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Abstract
Background: Cerebral ischemia and reperfusion (CIR) is a pathological condition characterized by a first blood
supply restriction to brain followed by the consequent restoration of blood flow and simultaneous
reoxygenation.
The aim of this study was to evaluate the neuroprotective effects of Tuscan black kale sprout extract (TBK-SE)
bioactivated with myrosinase enzyme, assessing its capability to preserve blood–brain barrier (BBB), in a rat
model of CIR.
Methods: CIR was induced in rats according to a classic model of carotid artery occlusion for a time period
of 1 h and the reperfusion time was prolonged for seven days.
Results: By immunohistochemical evaluation and western blot analysis of brain and cerebellum tissues, our
data have clearly shown that administration of bioactive TBK-SE is able to restore alterations of tight junction
components (claudin-5 immunolocalization). Also, bioactive TBK-SE reduces some inflammatory key-markers
(p-selectin, GFAP, Iba-1, ERK1/2 and TNF-α), as well as the triggering of neuronal apoptotic death pathway
(data about Bax/Bcl-2 balance, p53 and cleaved-caspase 3) and the generation of radicalic species by
oxidative stress (results focused on iNOS, nitrotyrosine and Nrf2).
Conclusion: Taken together, our findings lead to believe that bioactive TBK-SE exerts pharmacological
properties in protecting BBB integrity through a mechanism of action that involves a modulation of
inflammatory and oxidative pathway as well into control of neuronal death.
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Background
Cerebral ischemic stroke regards for approximately 80 %
of all strokes [1] and often it results from the occlusion
of a cerebral artery caused by a thrombus or embolus
that leads to an immediate loss of the normal intake of
oxygen and glucose to cerebral tissues [2].
Ready initiation of reperfusion is the most effective
treatment for reducing infarct area and behavioural defi-
cits caused by ischemia. Paradoxically, however, blood
flow restoration is causative of additional injury during
the cascade of events that characterize and identify the
so-called cerebral ischemia/reperfusion (CIR) injury [3].
It has been widely demonstrated that excitotoxicity,
ionic imbalance, adhesion molecules upregulation, react-
ive oxygen and nitrogen species (ROS/RNS) formation,
inflammation and apoptosis are the main mechanisms
involved in CIR [4, 5]. It is well known also that all these
events contribute to blood–brain barrier (BBB) break-
down, considered as a critical step in cerebral ischemia
pathogenesis [6].
BBB integrity and maintenance of homeostasis in cen-
tral nervous system (CNS) are critically dependent of
tight junctions (TJs) between cerebrovascular endothelial
cells. Any abnormality in the structure or function of TJs
can lead to BBB dysfunction that consequently may con-
tribute to the development of neurological damage [6].
Several experimental data showed that oxidative stress
may affect TJ components of BBB through the activation
of several pathways [7]. In fact, during CIR, production
of ROS is dramatically increased and involves endogen-
ous antioxidant systems leading to oxidative stress and
ultimately contributing to neuronal cell death [8].
For this reason, antioxidants have been the focus of
studies for developing neuroprotective drugs to be used
in cerebral ischemia treatment. To date there is no clin-
ically effective therapy for stroke management except
tissue-plasminogen activator (t-PA) [9].
In this scenario, growing interest has been focused on
the neuroprotective properties of natural compounds
and glucosinolates (GLs), a group of secondary metabo-
lites found in Brassica vegetables (Cruciferae), in helping
to maintain human health [10]. Increased consumption
of cruciferous vegetables has been associated with a de-
creased risk of several cardiovascular and neurodegener-
ative diseases [11–13]. In specific, the hydrolysis of GLs
by the plant enzyme myrosinase (Myr) results in the for-
mation of corresponding biologically active compounds,
the isothiocyanates (ITCs) [14]. To date, more than 120
GLs have been identified in plant [15]. Among them,
one of the most studied is RS-(−)-glucoraphanin [GRA;
4(RS)-methylsulfinylbutyl glucosinolate] a thiosaccharidic
compound found notably in Tuscan black kale (Brassica
oleracea L. var. acephala sabellica), for its numerous
properties as antinflammatory as well as antioxidant
agent, especially for neurodegenerative diseases treat-
ment [12, 16–18].
In the light of these recent findings, the purpose of
our study was to investigated whether a freeze-dried
Tuscan black kale sprouts extract containing about 15 %
of GRA and other minor GLs and bioactivated with Myr
(bioactive TBK-SE) has neuroprotective effects in a
chronic experimental model of CIR. Also, we investi-
gated the possible neuroprotective role of bioactive
TBK-SE, as a novel important field of action potentially
applicable in BBB dysfunctions through a repair mech-
anism at the level of TJs proteins and thus, the progres-
sion of neurological injury.
Finally, other important aim of this study was to suggest
this natural extract as a promising source of alternative
medicine for the prevention and/or treatment of cerebral
ischemia. In addition, as being a natural phytochemical,
we believe that bioactive TBK-SE could be introduced as
an herbal medicine without adverse effects, at least in as-
sociation with current conventional therapies.
Methods
Plant source and extract preparation
Ripe seeds of Tuscan black kale (Brassica oleracea (L.)
ssp acephala (DC) var. Sabellica L. cv. 0D74) were sup-
plied by Suba Seeds Company (Longiano, FC, Italy) and
stored in a dry and dark place at room temperature.
Seeds were identified by a lot number and guaranteed by
the producer for the quality and the homogeneity of the
product. Seeds were surface sterilised by soaking for
30 min in 1 % sodium hypochlorite and rinsed with tap
water. Sprouts were grown at room temperature by
using an automatic sprouter VitaSeed (Suba Seeds,
Longiano, FC, Italy) under an 8 h/16 h light/dark cycle.
Four-day old sprouts were gently washed with tap water,
whole frozen, freeze-dried and ground to a fine powder.
Fine powdered freeze-dried sprouts (30 g) were extracted
in boiling 70 % (v/v) ethanol (800 ml) for 5 min at 80 °C
using an Ultra-Turrax T25 homogenizer (IKA-Werk,
Staufen, Germany), and then centrifuged with a J2-MC
centrifuge (Beckman, Palo Alto, CA, USA) at 17,700 g for
40 min at 10 °C. The solid residue was extracted a second
time with the same w/v ratio and centrifuged as before.
The two supernatants were collected and the volume was
reduced three fold in a rotary evaporator at a temperature
of 40 °C. The concentrated extract was kept in an ice bath
overnight. Precipitated proteins were removed by centrifu-
gation, and finally the extract was freeze-dried (DLAB
500, Italian Vacuum Technology).
Determination of glucosinolate content
TBK-SE was analysed for GL profile and content accord-
ing to the EU official ISO 9167–1 method [19] which is
based on the HPLC analysis of desulfo-GL, as previously
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described [20]. Eight independent HPLC determinations
were performed.
Myrosinase purification
The enzyme myrosinase (Myr) was isolated from seeds
of Sinapis alba L. according to a reported method with
some modifications [21]. Briefly, the enzyme was ex-
tracted from white mustard seeds with water and puri-
fied by affinity chromatography on Con A-Sepharose.
Then, the active fractions coming from affinity chroma-
tography were pooled and dialyzed against 50 mM phos-
phate buffer pH 6.5 containing 0.15 M NaCl. The
dialyzed Myr solution was concentrated and loaded into
a prepacked Superdex 200 HiLoad 26/60 gel filtration
column (GE Healthcare) equilibrated with 50 mM phos-
phate buffer pH 6.5 containing 0.15 M NaCl connected
with a fast protein liquid chromatography system (AKTA
FPLC System, GE Healthcare, Milan, Italy). The active
fractions were pooled and concentrated by Millipore
Amicon Stirred Cell Model 8400 using a UF membrane
30 KDa MWCO (Millipore). The stock solution used in
the present study had a specific activity of 60 units/mg
of soluble protein. The enzymatic activity was 32 U/ml
and the solution was stored at 4 °C in sterile saline solu-
tion at neutral pH until use. One Myr unit was defined
as the amount of enzyme able to hydrolyze 1 μmol/min
of sinigrin at pH 6.5 and 37 °C.
Animals
Male Sprague–Dawley rats (about 9 weeks old) (Harlan,
Italy) 200–250 g weight were used. Rats were housed in
a controlled environment and provided with standard
rodent chow and water. Animal care was in compliance
with Italian regulations on protection of animals used
for experimental and other scientific purposes (D.M.
116/92) as well as with the EEC regulations (O.J. of
E.C.L 358/1 12/18/1986).
Ethics statement
This study was carried out in strict accordance with the
recommendations in the guide for the care and use of la-
boratory animals of the National Institutes of Health.
The protocol was approved by the Ministry of Health
“General Direction of animal health and veterinary
drug”. In particular, animal care was in compliance with
Italian regulations on protection of animals used for ex-
perimental and other scientific purposes (D.M. 116/92)
as well as with the EEC regulations (O.J. of E.C.L 358/1
12/18/1986). Also, it was minimized number of animals
used for this experiment and their suffering.
Cerebral ischemia/reperfusion (CIR) induction
After anaesthesia induced with an anaesthetic cocktail
composed of tiletamine plus xylazine (1 ml/Kg i.p.), CIR
was induced in rats according to a standardized method
already used in our previous published study of 2014
[22] that originally was described by Awooda et al. [23]
making some modifications. In brief, in the supine pos-
ition, a midline ventral incision was made in the neck of
each animal; the left carotid artery was exposed, sepa-
rated from the vagus nerve and occluded for 1 h by
clamping with small vascular clips and by inducing
hypotension to generate a cerebral ischemia animal
model. A phase of reperfusion of blood flow of the dur-
ation of seven days was followed.
Blood pressure was continuously monitored through a
blood pressure recorder (Ugo Basile, Varese, Italy), a non
invasive method that allows to check on a display the
systolic and diastolic blood pressure of rat during the
surgical procedures by the application of a tail cuff. This
allowed to ascertaining the reduction of blood flow fol-
lowing carotid artery occlusion and the increasing after
blood flow restoration. In specific, before the start surgi-
cal procedures, it was recorded a baseline blood pressure
value of about 108 ± 5 mmHg in rats and a blood pres-
sure value of about 49 ± 5 mmHg immediately after the
clamping, indicating that cerebral ischemia was success-
ful induced. Following removal of vascular clip, blood
pressure returned to the value of about 108 ± 5 mmHg.
In addition, during the observation period of seven
days, we have recorded eyelid edema associated to
hemorrhagic lachrymation in animal subjected to CIR,
further indicating that there had been alteration in cere-
bral blood flow circulation.
Myrosinase bioactivation of TBK-SE and animal treatment
TBK-SE was dissolved in PBS solution pH 7.2 at room
temperature and before rat i.p. treatment, the action of
Myr (17 mg TBK-SE, containing 2.6 mg GRA)/rat plus
20 μl Myr enzyme/1 ml) for 15 min at 37 °C allowed
having bioactive TBK-SE quickly.
Experimental groups
Rats were randomly allocated into the following groups
(N = 20 total animals):
 Untreated CIR group: rats were subjected to 1 h of
carotid artery occlusion followed by 7 days of
reperfusion (N = 10);
 Bioactive TBK-SE-treated CIR group: rats were
subjected to surgical procedures described as above
and bioactive TBK-SE (17 mg TBK-SE/rat plus 20 μl
Myr enzyme/1 ml) was administered 15 min after
ischemia and daily for seven days (N = 10).
Among the experimental groups, “Myr-control” group
has not been provided because in our previous studies it
was tested that Myr injection alone was without effects.
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As shown, Myr injection did not display allergic effect
as no eosinophil cells were detected by hematocrit
analysis [22].
At the end of the experiment, blood was collected by
cardiac puncture and animals were euthanized. Brain
and cerebellum tissues were sampled and processed in
order to perform morphological evaluation and molecu-
lar biology analysis.
Immunohistochemical evaluation
At 7 days following CIR-induction, brains were sampled
and fixed in 10 % (w/v) PBS-buffered formaldehyde and
7 μm sections were prepared from paraffin-embedded
tissues. After deparaffinization with xylene, sections of
brain samples were hydrated in graded ethanol. Detec-
tion of claudin-5, p-selectin, GFAP and iNOS, Nitrotyro-
sine, Nrf2 and Bax was carried out after boiling in citrate
buffer 0.01 M pH 6 for 4 min. Endogenous peroxidase
was quenched with 0.3 % (v/v) hydrogen peroxide in 60 %
(v/v) methanol for 30 min. Nonspecific adsorption was
minimized by incubating the section in 2 % (v/v) normal
goat serum in PBS for 20 min.
Sections were incubated overnight with:
 anti-Claudin-5 monoclonal antibody (1:100 in PBS
v/v; Novus Biologicals);
 anti-p-selectin polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc.);
 anti-GFAP monoclonal antibody (1:50 in PBS v/v;
Cell Signaling Technology);
 anti-iNOS polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc.);
 anti-Nitrotyrosine polyclonal antibody (1:1000 in
PBS v/v; Millipore);
 anti-Nrf2 polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc.);
 anti-Bax polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc.).
Endogenous biotin or avidin binding sites were blocked
by sequential incubation for 15 min with biotin and avidin
(DBA, Milan, Italy), respectively. Sections were washed
with PBS and incubated with secondary antibody. Specific
labelling was detected with a biotin-conjugated goat
anti-rabbit IgG and avidin–biotin peroxidase complex
(Vectastain ABC kit, VECTOR). The counterstain was
developed with peroxidase substrate kit DAB (brown
colour) or DAB nickel solution addicted (black colour)
(Vector Laboratories, Inc.) and Hematoxylin (blue back-
ground) or nuclear fast red (Vector Laboratories, Inc.). To
verify the binding specificity, some sections were also in-
cubated with only the primary antibody (no secondary) or
with only the secondary antibody (no primary). In these
cases no positive staining was found in the sections,
indicating that the immunoreaction was positive in all the
experiments carried out.
All sections were obtained using light microscopy
(LEICA DM 2000 combined with LEICA ICC50 HD
camera). To perform densitometric analysis, quantitative
data were carried out using Leica Application Suite
V4.2.0 software.
Western blot analysis
All the extraction procedures were performed on ice using
ice-cold reagents. In brief, cerebellum tissues were sus-
pended in extraction buffer containing 0.32 M sucrose,
10 mM Tris–HCl, pH 7.4, 1 mM EGTA, 2 mM EDTA,
5 mM NaN3, 10 mM 2-mercaptoethanol, 50 mM NaF,
protease inhibitor tablets (Roche Applied Science, Monza,
Italy), and they were homogenized at the highest setting
for 2 min. The homogenates were chilled on ice for
15 min and then centrifuged at 1000 g for 10 min at 4 °C,
and the supernatant (cytosol +membrane extract from
brain tissue) was collected to evaluate content of citoplas-
matic proteins.
The pellets were suspended in the supplied complete
lysis buffer containing 1 % Triton X-100, 150 mM NaCl,
10 mM Tris–HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA
protease inhibitors (Roche), and then were centrifuged
for 30 min at 15.000 g at 4 °C. Then, supernatant contain-
ing nuclear extract was collected to evaluate the content
of nuclear proteins. Supernatants were stored at −80 °C
until use. Protein concentration in homogenate was esti-
mated by Bio-Rad Protein Assay (Bio-Rad, Segrate, Italy)
using BSA as standard, and 20 μg of cytosol and nuclear
extract from each sample were analyzed.
Proteins were separated on sodium dodecyl sulfate-
polyacrylamide minigels and transferred onto PVDF
membranes (Immobilon-P Transfer membrane, Millipore),
blocked with PBS containing 5 % nonfat dried milk (PM)
for 45 min at room temperature, and subsequently probed
at 4 °C overnight with specific antibodies for Phospho-p44/
42 MAPK (ERK1/2) (1:2000; Cell Signaling Technology),
Bcl-2 (1:500; Cell Signaling Technology), Bax (1:500;
Cell Signaling Technology), Nrf2 (1:100; Cell Signaling
Technology), Nitrotyrosine (1:2000; Millipore), Iba-1
(1:1000; Abcam), p53 (Abcam 1:2000;) and cleaved-
caspase 3 (1:500; Cell Signaling Technology), in 1x PBS,
5 % (w/v) non fat dried milk, 0.1 % Tween-20 (PMT).
HRP-conjugated goat anti-rabbit IgG or goat anti-mouse
IgG were incubated as secondary antibodies (1:2000; Santa
Cruz Biotechnology, Inc.) for 1 h at room temperature.
To ascertain that blots were loaded with equal amounts
of protein lysates, they were also incubated with antibody
for GAPDH HRP Conjugated (1:1000; Cell Signaling
Technology), p42 MAP Kinase (Erk 2) (1:1000; Cell
Signaling Technology) and beta-actin (1:1000; Santa Cruz
Biotechnology, Inc). The relative expression of protein
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bands was visualized using an enhanced chemilumines-
cence system (Luminata Western HRP Substrates,
Millipore) and proteic bands were acquired and quantified
with ChemiDoc™ MP System (Bio-Rad) and a computer
program (ImageJ software) respectively.
Blots are representative of three separate and reprodu-
cible experiments. The statistical analysis was carried out
on three repeated blot performed on separate experiments.
Blood sampling
At the sacrifice, blood samples were collected via cardiac
puncture in Serum Separator Tubes (Vacutainer® SSTTM
II Advance, BD Diagnostic, Milan, Italy) and centrifuged
following at least 30 min from the collection at 2000 g
speed for 10 min. The achieved serum was collected,
aliquoted and stored at −80 °C to be used in next
investigations.
TNF-α assay
ELISA kit for TNF-α parameter assay (R&D system Europe,
Ltd, Abingdon, UK) was purchased to detect TNF-α levels
in serum samples. The kit was used according to the manu-
facturer’s instruction and achieved O.D. were tabulated and
analyzed using a software of elaboration data.
Statistical analysis
Data were analyzed in GraphPad Prism version 6.0 (Graph-
Pad Software, La Jolla, CA). The results were analyzed by
unpaired Student’s t-test. A p value of < 0.05 was considered
to be statistically significant. All results achieved are pre-
sented as the means ± S.E.M. of n experiments.
Results
Glucosinolate content in TBK-SE and myrosinase
bioactivation
Individual and total content of GLs in TBK-SE are re-
ported in Table 1, and Fig. 1 shows a typical HPLC chro-
matogram of GLs present in the extract (Fig. 1). The
extract resulted to be highly enriched in GLs containing
21.1 % (w/w) of total GLs. The most abundant were two
aliphatic GL with sulfur-containing side chain, with pre-
dominant GRA, the precursor of R-sulforaphane, followed
by glucoerucin (GER, 4-methylsulfanylbutyl GL) the pre-
cursor of erucin, representing 72 % and 17 % of total GLs,
respectively. It is worth noting that, TBK-SE was free of
the goitrogenic progoitrin ((2S)-2-hydroxy-3-butenyl GL)
and contained only limited amount of indole GLs, 0.98 %
(w/w) 4-hydroxy-glucobrassicin (4-OH-GBS, 4-hydroxy-
3-indolylmethyl GL), 0.18 % (w/w) glucobrassicin (GBS, 3-
indolylmethyl GL), 0.21 % (w/w) 4-methoxy glucobrassicin
(4-OMe-GBS, 4-methoxy-3-indolylmethyl GL) and 0.67 %
(w/w) neoglucobrassicin (Neo-GBS, N-methoxy-3-indolyl-
methyl). Treatment of TBK-SE with Myr enzyme cata-
lyzed the quantitative transformation of aliphatic GLs into
ITCs, R-sulforaphane being the major one, as already de-
scribed [20], thus indole GLs are known to be hydrolysed
into highly unstable ITC and are spontaneously trans-
formed to carbinols.
Bioactive TBK-SE restores BBB vascular endothelium after
CIR induction
In order to evaluate whether BBB breakdown is accom-
panied by the loss or alterations of TJ-associated mole-
cules from the BBB TJs following CIR induction, we
investigated the claudin-5 expression by immunohisto-
chemical evaluation.
Sections obtained from CIR rats did not show positive
staining for claudin-5 in temporal lobe of brain tissue
(Fig. 2a) as well as at the level of vascular endothelium
of BBB in temporal lobe area of the brain (Fig. 2b). In
contrast, bioactive TBK-SE treatment normalized the
positive staining for claudin-5 in different districts, as
shown by immunohistochemical localization in brain
section and in BBB vascular endothelium of CIR rats
(Fig. 2c and d, see densitometric analysis Fig. 3).
Also, immunohistochemical localization of p-selectin
showed an increased expression of adhesion molecules
following CIR in the vascular endothelium (Fig. 2e),
while treatment with bioactive TBK-SE clearly reduced
the degree of positive staining for p-selectin in brain tis-
sues (Fig. 2f, see densitometric analysis Fig. 3).
Bioactive TBK-SE modulates GFAP and Iba-1expression
after CIR
Moreover, with the purpose to investigate the cellular
mechanisms by which the treatment with bioactive TBK-
SE may modulate the astrocyte activation during CIR, we
evaluated the GFAP expression by immunohistochemical
Table 1 Glucosinolate (GL) content of Tuscan black Kale (Brassica oleracea (L.) ssp acephala (DC) var. Sabellica L. cv. 0D74) sprout
extract
Aliphatic GLs Indole-type GLs Total GLs
GIB GRA GER 4-OH-GBS GBS 4-OMe-GBS Neo-GBS
μmol/g 6.5 ± 0.4 317.2 ± 8.2 79.5 ± 2.8 19.4 ± 1.8 3.7 ± 0.5 4.1 ± 0.2 13.0 ± 0.3 443.4 ± 14.2
mg/g 3.0 ± 0.2 150.9 ± 3.9 36.5 ± 1.3 9.8 ± 0.9 1.8 ± 0.2 2.1 ± 0.1 6.7 ± 0.2 210.8 ± 6.8
The data represent the mean ± SD of two replicates experiments with 4 samples analysed per replicate (n = 8)
GIB glucoiberin, GRA RS-(−)-glucoraphanin, GER glucoerucin, 4-OH-GBS 4-hydroxy glucobrassicin, GBS glucobrassicin, 4-OMe-GBS 4-methoxy glucobrassicin,
Neo-GBS neoglucobrassicin
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analysis. GFAP is considered a marker protein for astro-
gliosis. It was observed a marked positive staining for
GFAP in the sections from CIR rats, both in brain (Fig. 4a)
and cerebellum sections (Fig. 4b). In contrast, a reduction
of GFAP positive staining was evident in pharmacologic-
ally treated group (Fig. 4c and d, see densitometric ana-
lysis Fig. 5).
Also, western blot analysis showed that Iba-1 levels are
substantially increased in cerebellum samples collected
from CIR rats seven days after CIR induction, whereas
Iba-1 levels were attenuated by approximately 50 % with
bioactive TBK-SE administration (Fig. 4e).
Bioactive TBK-SE regulates iNOS, nitrotyrosine and Nrf2
expression
To determine the role of nitric oxide (NO) produced dur-
ing CIR and to verify whether treatment with bioactive
TBK-SE is able to counteract oxidative and nitrosative
stress resulting from ischemic damage, we evaluated iNOS
and nitrotyrosine expression by immunohistochemical
and western blot analysis, after seven days of reperfusion.
Immunohistochemical localization of iNOS in temporal
lobe area of brain tissues of untreated-CIR rats (Fig. 6a)
sampled showed an increased expression of this marker
following CIR, while treatment with bioactive TBK-SE sig-
nificantly reduces the degree of positive staining for iNOS
(Fig. 6b, see densitometric analysis Fig. 5).
Brain sections obtained from CIR untreated rats ex-
hibited positive staining for nitrotyrosine in cortex
(Fig. 7a), hippocampus (Fig. 7b), brainstem (Fig. 7c)
and cerebellum (Fig. 7d) of CIR rats, while rats
treated with bioactive TBK-SE showed negative stain-
ing for nitrotyrosine (Fig. 7e, f, g, h, see densitomet-
ric analysis Fig. 5).
In addition, we analyzed cerebellum expression levels of
nytrotirosine by western blot analysis. This displayed a sig-
nificant increase in nytrotirosine expression in cerebellum
samples collected 7 days after CIR-induction from un-
treated rats. Conversely, cerebellum levels of nytrotirosine
were reduced by administration of bioactive TBK-SE
(Fig. 7i).
Moreover, it is known that GLs may exert their
cytoprotective effects by the ability to induce expres-
sion of several enzymes via the Keap1/Nrf2/ARE
pathway. Western blot analysis showed a basal level
of Nrf2 expression in samples obtained from CIR
rats. Treatment of rats with bioactive TBK-SE signifi-
cantly increased Nrf2 expression () (Fig. 8i). The
same result was obtained from immunohistochemical
evaluation for Nrf2, showing a positive staining in
cortex (Fig. 8a), hippocampus (Fig. 8b), brainstem
(Fig. 8c) and cerebellum (Fig.8d) of CIR rats treated
with bioactive TBK-SE, and a negative staining in
brain of CIR rats (Fig. 8e, f, g, h, see densitometric
analysis Fig. 5).
Fig. 1 HPLC chromatogram of glucosinolates (GLs) isolated from Tuscan black kale (Brassica oleracea (L.) ssp acephala (DC) var. Sabellica L. cv.
0D74) sprout extract. GIB, glucoiberin; GRA, RS-(−)-glucoraphanin; GER, glucoerucin; 4-OH-GBS, 4-hydroxy glucobrassicin; GBS, glucobrassicin,
4-OMe-GBS, 4-methoxy glucobrassicin; Neo-GBS, neoglucobrassicin
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Effect of bioactive TBK-SE on Phospho-p44/42 MAPK
(ERK1/2) expression and TNF-α following CIR
To investigate the cellular mechanisms whereby treat-
ment with bioactive TBK-SE attenuates the development
of CIR, we also evaluated the level of ERK1/2 which re-
sults in expression of pro-inflammatory genes mediating
the inflammatory characteristic of CIR. The activation of
MAPK pathways in particular the phosphorylation of
ERK1/2 expression was investigated by western blot ana-
lysis in cerebellum tissue. ERK1/2 levels were appre-
ciably increased in cerebellum samples taken from rats
subjected to CIR, while the treatment of rats with bio-
active TBK-SE reduced levels of ERK1/2 (Fig.9a). Also,
in order to investigate whether treatment with bioactive
TBK-SE can modulate the inflammatory processes trig-
gered by CIR induction through regulating secretion of
pro-inflammatory cytokines, the expression levels of
TNF-α, serum samples was quantified by ELISA assay.
Our results showed that serum levels are significantly
higher in untreated CIR rats when compared with serum
levels of animals treated with bioactive TBK-SE (Fig. 9b).
Bioactive TBK-SE treatment inhibits CIR-induced apoptosis
At seven days after CIR, the appearance of proteic effec-
tors of mitochondrial apoptosis, such as pro-apoptotic
Bax proteins, was evaluated by immunohistochemical
evaluation and western blot. Immunohistochemical
evaluation for Bax was performed in different areas of
Fig. 2 Bioactive TBK-SE restores BBB vascular endothelium. Sections from CIR rats did not show positive staining for claudin-5 in temporal lobe
of brain tissue (a) as well as at the level of vascular endothelium of BBB in temporal lobe area of the brain (b). In contrast, in both two sections
obtained from bioactive TBK-SE-treated rats it was observed a normal distribution of claudin-5 (c and d). Also, immunohistochemical localization
of p-selectin displayed an increased expression of adhesion molecules following CIR in the vascular endothelium (e), while treatment with bioactive
TBK-SE clearly reduced the degree of positive staining for p-selectin in brain tissues (f)
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brain tissues. Specifically, a positive staining was found
in cortex (Fig. 3a), hippocampus (Fig. 3b), brainstem
(Fig. 3c) and cerebellum (Fig. 3d) of CIR rats. On the
contrary, treatment with bioactive TBK-SE significantly
reduces the degree of positive staining for Bax in all the
same regions of the brain (Fig. 3e, f, g, h, see densitomet-
ric analysis Fig. 5). Also, by western blot was found that
Bax levels were increased substantially in cerebellum tis-
sues from CIR rats. On the contrary, bioactive TBK-SE
treatment prevented the CIR-induced Bax expression
(Fig. 3i).
Likewise, to detect Bcl-2 expression, extracts from
cerebellum tissues of rats were also analyzed by Western
blot analysis. A basal level of Bcl-2 expression was de-
tected in samples from CIR rats. Treatment of rats with
bioactive TBK-SE significantly attenuated CIR-induced
inhibition of Bcl-2 expression (Fig.3i).
In addition, proteins in the mitochondrial p53 pathway
were detected by western blot analysis in cerebellum
samples. Our data showed a significant expression of
p53 in samples collected seven days after CIR-induction.
Conversely, levels of p53 were clearly reduced by admin-
istration of bioactive TBK-SE (Fig. 10a).
Finally, sequential activation of caspases plays a central
role in the execution-phase of cell apoptosis, leading to
programmed cell death by cleavage of cellular substrates.
By western blot analysis, we have evaluated the activa-
tion of cleaved-caspase 3. Cleaved-caspase 3 levels were
appreciably increased in the cerebellum from rats sub-
jected to CIR. On the contrary, treatment with bioactive
TBK-SE prevented CIR-induced cleaved-caspase 3 ex-
pression (Fig. 10b).
Discussion
Ischemic stroke is the result of a transient or permanent
reduction in cerebral blood flow caused by occlusion of
a cerebral artery via an embolus or local thrombosis
[24]. After the primary neuronal cell injury, secondary
Fig. 3 Bioactive TBK-SE treatment modulates unbalance between Bax and Bcl-2. Bax was evaluated by immunohistochemical evaluation in brain
sections after CIR induction. Brain sections obtained from CIR untreated rats exhibited positive staining for Bax in cortex (a), hippocampus (b),
brainstem (c) and cerebellum (d) of CIR rats, while rats treated with bioactive TBK-SE showed negative staining for Bax in cortex (e), hippocampus
(f), brainstem (g) and cerebellum (h). Panel I shows ratio between Bax and Bcl-2 in cerebellum tissues, showing an higher expression of Bax/Bcl-2
in CIR untreated rats, attenuated by administration of bioactive TBK-SE (i). GAPDH was used as internal control. **p < 0.05 vs CIR
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neuronal damage, known as reperfusion injury occurs
and exacerbates initial damage [3, 25]. It is well known
that cerebral ischemia rapidly raises inflammatory re-
sponses in brain, by activating different resident cell
populations such as endothelial cells, microglia and as-
trocytes, as well as inflammatory cytokines release,
thereby contributing to BBB breakdown [26, 27]. In fact,
BBB disruption is considered as a critical event in the
pathogenesis of cerebral stroke. However the molecular
mechanisms involved are not completely understood [6].
Among various components of the BBB, the tight
junction (TJs) protein claudins are the most widely stud-
ied, which are critical for maintaining the BBB structural
integrity and permeability. The disruption of the cere-
brovascular claudin-5 has been strongly correlated with
the dynamic event of BBB breakdown after cerebral
Fig. 4 Effects of Bioactive TBK-SE on GFAP and Iba-1 expression. The immunohistochemical analysis for GFAP showed that positive staining for
GFAP was observed in the tissues obtained from CIR rats both in brain (a) as well as in cerebellum sections (b). In contrast, a reduction of GFAP
positive staining was evident in bioactive TBK-SE-treated group in both two different areas (c and d). By western blot analysis it has been shown
a significant increase Iba-1 expression in cerebellum samples collected from CIR rats seven days after CIR induction. Conversely, levels of Iba-1
were attenuated by administration with bioactive TBK-SE attenuated Iba-1 levels by approximately 50 % (e). GAPDH was used as internal control.
**p < 0.05 vs CIR
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ischemia [28, 29]. Immunohistochemical evaluation was
performed to demonstrate that CIR induced changes in
claudin-5 expression and as well as bioactive TBK-SE is
able to control TJs permeability, modulating claudin-5
expression.
Following an impairment of BBB, peripheral leuko-
cytes infiltrate into the brain and the normally immune-
privileged cerebral environment is exposed to systemic
responses that further aggravate inflammation and brain
injury [30].
According to Jin R. et al. [31], our data have revealed
an increased expression of p-selectin, an adhesion mol-
ecule that stimulates rolling of leukocytes and other in-
flammatory cell infiltration following induced damage,
demonstrating that it was modulated by bioactive TBK-
SE administration. With regard to the untreated rats the
up-regulation of p-selectin seems to reflect both in-
creased expression of the endothelial cells and the
binding of p-selectin positive platelets to the vessel wall,
leading in turn an exacerbation of the neuroinflamma-
tion status [32].
In addition, we evaluated expression of Iba-1, a novel
calcium-binding protein that plays an important role in
regulation of microglia function, in which it is specifically
expressed [33]. Also, it was found that Iba-1 expression is
up-regulated in microglia following cerebral ischemia [33].
Indeed, according to Ohsawa et al. [34], seems that Iba-1
is involved in the Rho family of small GTPase, Rac, and
calcium signaling pathways and may be required for cell
mobility and phagocytosis of microglia/macrophages.
Once activated, microglia develops macrophage-like
capabilities including cytokine production, antigen presen-
tation and the release of matrix metalloproteinases that
weaken the BBB [35]. Our data confirmed an up-regulation
of Iba-1 in CIR rats compared with pharmacologically-
treated ones. Moreover, looking at proinflammatory
Fig. 6 Bioactive TBK-SE modulates production of i-NOS. iNOS was evaluated by immunohistochemical analysis in brain sections 7 days after CIR.
Brain sections obtained from CIR rats exhibited positive staining for iNOS (a). Bioactive TBK-SE treatment reduced the degree of positive staining
for iNOS in lobe temporal area of brain (b)
Fig. 5 Densitometric analysis for claudin-5, p-selectin, GFAP and i-NOS, nitrotyrosine, Nrf2 and Bax. For immunohistochemical images, densitometric
analysis was carried out to quantify and highlight significant differences among experimental groups. p value <0.05 was considered significant
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cytokine profile classically activated by microglia during
CIR, levels of TNF-α result significantly decreased follow-
ing bioactive TBK-SE treatment.
It was consistently demonstrated that astrocytes the
most abundant population of glial cells, are essential for
brain homeostasis and maintenance and maturation of
the BBB [36–38]. While astrocytes show a good capabil-
ity repairing in many CNS processes, they are also cap-
able of secreting inflammatory factors such as cytokines
and chemokines, which aggravate brain damage [39]. In
fact, astrocytes were found to play an important role also
in CIR injury [40].
Moreover, the induction of Nrf2-mediated transcrip-
tion, particularly in astrocytes, has been shown to pro-
tect against neurotoxicity from a variety of injuries, such
as cerebral ischemia [41, 42]. According to other studies
reported in literature, Nrf2 could play a protective action
in astrocytes, decreasing GFAP expression probably
through the mechanism related to the glutathione activity
[43, 44]. Our results confirmed that treatment with bio-
active TBK-SE in CIR rats leads to an upregulation of Nrf2
expression, while GFAP expression was significantly inhib-
ited. This balance prevents that GFAP expressing astro-
cytes may regulate the integrity of BBB, damaging TJ
components and interfering with the normal astrocyte in-
teractions [45–47]. Probably, astrocyte specific Nrf2-me-
diated protection due to treatment with bioactive
TBK-SE could have beneficial effects in counteracting
the damage after CIR and this could be associated
with the production of several growth factors that
may protect neurons from damage.
The local accumulation of NO is also involved in the
inflammatory cascade after cerebral ischemia [48, 49].
This mediator enhances cell adhesion molecules expres-
sion on endothelial cells and promotes adhesion and
transendothelial migration of immune cells [50]. The
role of iNOS in ischemia is yet controversial, it was
demonstrated that has a beneficial role as modulator or
Fig. 7 Bioactive TBK-SE modulates nitrotyrosine expression. Nitrotyrosine was evaluated by immunohistochemical evaluation in brain sections
after CIR induction. Brain sections obtained from CIR untreated rats exhibited positive staining for nitrotyrosine in cortex (a), hippocampus (b),
brainstem (c) and cerebellum (d) of CIR rats, while rats treated with bioactive TBK-SE showed negative staining for nitrotyrosine in cortex (e),
hippocampus (f), brainstem (g) and cerebellum (h). By western blot analysis nitrotyrosine expression was evaluated. It was found a significant
increase in nytrotirosine expression in cerebellum samples collected 7 days after CIR-induction from untreated rats. Conversely, cerebellum levels
of nytrotirosine were reduced by administration of bioactive TBK-SE (i). GAPDH was used as internal control. ***p < 0.05 vs CIR
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messenger but during oxidative stress condition it is po-
tentially toxic [51]. In fact, over-production of NO
through iNOS causes accentuated lipid peroxidation,
protein and DNA modifications that result in cellular
damage [52]. Our study demonstrates that bioactive
TBK-SE reduces the expression of iNOS in tissues from
CIR treated rats. Likewise our results demonstrated that
bioactive TBK-SE reduced the generation of reactive spe-
cies through the evaluation of nitrotyrosine expression,
chosen as an indirect marker of peroxynitrite activity.
MAP kinase (MAPKs) pathway, investigated through
detection of ERK1/2 expression, resulted upregulated in
CIR-related mechanisms of pathology but attenuated by
bioactive TBK-SE administration.
Although it has been demonstrated that ERK1/2 is a
pro-survival factor in the MAP kinase family and con-
tributes to the regulation of cell proliferation and differ-
entiation, under some circumstances, it can function in
a pro-apoptotic manner in the neuronal system [53, 54].
Protective effects of bioactive TBK-SE in counteracting
apoptosis are evaluable looking to the main apoptosis-
regulatory genes, such Bax and Bcl-2.
The changes in the Bax to Bcl-2 ratio have also been
studied in several experimental ischemic models proving
that excess of Bcl-2 promotes cell survival, while Bax ex-
cess induces cell death. Our data showed an up-
regulation of Bcl-2 and a downregulation of Bax in
pharmacologically-treated rats.
The transcription factor and mediator of apoptosis
p53 was also found to be upregulated following stroke
[55]. p53 is able to induce apoptosis both by controlling
translation of pro-apoptotic p53-checked mediators and
by non-transcriptional mechanisms [56], including up-
regulation of pro-apoptotic Bax and downregulation of
Bcl-2 [57, 58].
In specific, according to Leker at al [55], translocation
of resident p53 into the nucleus is an early event in p53-
induced apoptosis in ischemic brain cells and that the
prevention of this early translocation could reduce brain
damage. Our data showed an increased nuclear expres-
sion in brain ischemic tissues, on the contrary attenu-
ated by treatment with bioactive TBK-SE.
Also, supporting above cited results and adding further
evidences about effects of bioactive TBK-SE, we found a
Fig. 8 Effects of Bioactive TBK-SE on Nrf2 expression. Negative staining for Nrf2 was observed in cortex (a), hippocampus (b), brainstem (c) and
cerebellum (d) of CIR rats. On the contrary, positive staining for Nrf2 was observed in cortex (e), hippocampus (f), brainstem (g) and cerebellum
(h) from rats treated with bioactive TBK-SE. Also, western blot analysis showed a basal level of Nrf2 expression in cerebellum samples obtained
from CIR rats. Bioactive TBK-SE treatment significantly increased Nrf2 expression (i). GAPDH was used as internal control. *p < 0.05 vs CIR
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modulated cleaved-caspase 3 activity in CIR pharmaco-
logically treated rats.
A protective effect of bioactive TBK-SE suggests that
this treatment could interfere with the CIR-induced
neuronal death, preserving cells by the injury.
Conclusion
Alternative medicine is an interesting research field in to
discovering potential active substances found in nature
for a wide range of applications. As a consequence, our
efforts were recently focused to provide new candidates,
primarily natural product extracts, for the prevention
and treatment of neurological diseases. Here, our results
show that bioactive TBK-SE could represent a good and
effective approach in the treatment of experimental CIR.
This study was designed and performed in light of the
results achieved by our research group in a previous
paper [22] in which we investigated the neuroprotective
effects of RS-(−)-glucoraphanin purified from Tuscan
Fig. 9 Western blot analysis of ERK1/2 expression and ELISA assay
for TNF-α. ERK1/2 expression levels normalized on ERK2 display an
increase in rats subjected to CIR, while administration of bioactive
TBK-SE reduces levels of ERK1/2 (a). ERK2 was used as internal
control. **p < 0.05 vs CIR. ELISA assay showed that serum levels of
TNF-α are significantly higher in untreated CIR rats when compared
with TNF-α serum levels of animals treated with bioactive TBK-SE (b).
**p < 0.05 vs CIR
Fig. 10 Western blot analysis for p53 and Cleaved-caspase3 expression.
p53 expression was detected by western blot analysis. Our data showed
a significant expression of p53 in samples collected seven days after
CIR-induction. Conversely, levels of p53 were clearly reduced by
administration of bioactive TBK-SE (a). GAPDH was used as internal
control. **p < 0.05 vs CIR. By western blot analysis the activation of
cleaved-caspase 3 was evaluated. CIR caused a significant increase
in cleaved-caspase 3 expression. On the contrary, treatment with
bioactive TBK-SE prevented the CIR-induced caspase 3 expression
(b). GAPDH was used as internal control. **p < 0.05 vs CIR
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black kale seeds and bioactivated with myrosinase en-
zyme in an acute experimental model of CIR. Using this
model it was clearly demonstrated that the released R-
sulforaphane is active on central and peripheral nervous
system, through mechanisms which involved both the
modulation of the inflammatory pathways and the re-
duction in the activation of cell death by apoptosis. In
specific, it was proved that bioactive RS-(−)-glucorapha-
nin is able to significantly reduce NF-kB translocation
and intercellular adhesion molecule 1 (ICAM-1), as well
as the triggering of oxidative species generation (iNOS),
and neuronal apoptotic death pathway [22].
Finally, the latest findings obtained by chronic experi-
mental model of CIR lead to believe that bioactive TBK-
SE exerts pharmacological properties in protecting BBB
integrity through a mechanism of action that involves a
modulation of the inflammatory and oxidative pathway
as well into the control of neuronal death by apoptosis.
In summary, the relevance of the present study con-
sists in the possible use of bioactive TBK-SE, as a novel
natural product for the treatment of damage associated
with CIR. The benefit could be ascribed to either as an
herbal medicine readily available and both as a safe and
well tolerated product that could be used in neuropro-
tection in cerebral ischemia/reperfusion injury, at least
in association with current conventional therapies.
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